InvestorsObserver
×
News Home

Should Biotechnology Stock Novavax, Inc. (NVAX) Be in Your Portfolio Monday?

Monday, June 27, 2022 12:19 PM | InvestorsObserver Analysts

Mentioned in this article

Should Biotechnology Stock Novavax, Inc. (NVAX) Be in Your Portfolio Monday?

A rating of 0 puts Novavax, Inc. (NVAX) near the bottom of the Biotechnology industry according to InvestorsObserver. Novavax, Inc.'s score of 0 means it scores higher than 0% of stocks in the industry. Novavax, Inc. also received an overall rating of 0, putting it above 0% of all stocks. Biotechnology is ranked 36 out of the 148 industries.

Overall Score - 0
NVAX has an Overall Score of 0. Find out what this means to you and get the rest of the rankings on NVAX!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.
This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Novavax, Inc. Stock Today?

Novavax, Inc. (NVAX) stock is trading at $52.70 as of 12:06 PM on Monday, Jun 27, a rise of $1.03, or 1.99% from the previous closing price of $51.67. The stock has traded between $50.16 and $53.70 so far today. Volume today is less active than usual. So far 2,392,740 shares have traded compared to average volume of 7,066,931 shares. Click Here to get the full Stock Report for Novavax, Inc. stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App